Sino Biopharmaceutical Ltd's Fiscal Year is From January To December - All Figures are in HKD, Billions.
The item "Research-and-Development" stands at 5.62 Billion Hong Kong Dollars for the trailing twelve months (TTM) period ending 06/30/2025, the highest value at least since 12/31/2012, the period currently displayed.
Sino Biopharmaceutical Ltd's second quarter result of 1.59 Billion HKD for the item "Research and Development" represents no change compared to it's first quarter result.
Also, Sino Biopharmaceutical Ltd's second quarter result of 1.59 Billion HKD for the item "Research and Development" represents an increase of 32.80 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sino Biopharmaceutical Ltd's second quarter result of 5.62 Billion HKD for the item "Research and Development" represents an increase of 7.53 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 125.90 percent compared to the value the year prior.
The 1 year change in percent is 125.90.
The 3 year change in percent is 40.09.
The 5 year change in percent is 138.81.
The 10 year change in percent is 431.12.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Research and Development | 905,699,262,464.00 |
![]() | Johnson & Johnson - Research and Development | 486,508,953,600.00 |
![]() | AbbVie Inc - Research and Development | 399,570,305,024.00 |
![]() | Roche Holding AG - Research and Development | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Research and Development | 280,205,508,085.11 |